Bicara Therapeutics to Present Clinical Data from Lead Precision Tumor Modulator Program, BCA101, at ESMO Congress 2022
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that it will present updated data from the expansion phase of its ongoing Phase 1 trial of BCA101, a bifunctional antibody designed to target the TGFβ trap to EGFR+ … [Read more…]
